Format

Send to

Choose Destination
J Comp Eff Res. 2018 Oct;7(10):947-958. doi: 10.2217/cer-2018-0020. Epub 2018 Aug 31.

Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.

Author information

1
Evidera, Inc., Montreal, Canada.
2
Evidera, Inc., San Francisco, CA 94111, USA.
3
Pfizer Ltd, Walton Oaks, Surrey, UK.
4
Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, UK.
5
University of Manchester Institute of Cancer Sciences & The Christie NHS Foundation Trust, Manchester, UK.

Abstract

AIM:

A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111).

METHODS:

The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus.

RESULTS:

The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39-1.89) for PFS and 0.82 (0.53-1.27) for OS.

CONCLUSION:

Findings indicate comparable PFS and OS with sunitinib and everolimus.

KEYWORDS:

MAIC; comparative effectiveness; everolimus; matching-adjusted indirect comparison; sunitinib

PMID:
30168349
DOI:
10.2217/cer-2018-0020

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center